Alexander Mauskop
New York, NYNPI 1962629147
Payments from drug & device makers
Across 1,463 payments — averaging $397.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$281K
- Lilly USA, LLC$103K
- Lundbeck LLC$81K
- Amgen$66K
- Teva Pharmaceuticals USA, Inc.$35K
- Pfizer$6K
- plus $10K from 23 others
What the payments were for
- Consulting fees$50,5449%
- Speaking & faculty fees$478,20682%
- Grants$880%
- Travel & lodging$26,2285%
- Food & beverage$26,0804%
- Education$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 653 | $281,114 |
| Lilly USA, LLC | 174 | $103,326 |
| Lundbeck LLC | 84 | $80,868 |
| Amgen | 89 | $66,128 |
| Teva Pharmaceuticals USA, Inc. | 86 | $34,588 |
| Pfizer | 63 | $5,652 |
| Biohaven Pharmaceutical Holding Company Ltd. | 22 | $2,620 |
| Biohaven Pharmaceuticals, Inc. | 126 | $1,574 |
| Biodelivery Sciences International, Inc. | 1 | $1,500 |
| Avanir Pharmaceuticals, Inc. | 2 | $1,126 |
| Upsher-smith Laboratories LLC | 52 | $602 |
| Novartis | 15 | $504 |
| Amneal Pharmaceuticals LLC | 13 | $286 |
| Supernus Pharmaceuticals, Inc. | 19 | $275 |
| Assertio Therapeutics, Inc. | 39 | $272 |
| Axogen | 1 | $204 |
| Boston Scientific | 2 | $160 |
| Revance Therapeutics, Inc. | 1 | $117 |
| Idorsia Pharmaceuticals US Inc | 4 | $77 |
| Scilex Pharmaceuticals Inc. | 4 | $64 |
| Zyla Life Sciences, Inc. | 4 | $53 |
| Novo Nordisk | 1 | $46 |
| Medtronic | 1 | $36 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Endo Pharmaceuticals Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $20 |
| Tonix Medicines, Inc. | 1 | $18 |
| Impel Pharmaceuticals LLC | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$148,994
- UBRELVY$119,392
- VYEPTI$79,392
- AIMOVIG$65,259
- EMGALITY$59,875
- REYVOW$43,861
- AJOVY$33,703
- QULIPTA$24,461
- NURTEC ODT$5,804
- ELYXYB - CELECOXIB$1,500
- ONZETRA$1,126
- AVANCE NERVE GRAFT$204
- Watchman$149
- DAXXIFY$117
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 17 | $68,285 |
| Nurtec OdtRimegepant Sulfate | 34 | $59,602 |
| OxycontinOxycodone Hcl | 52 | $48,308 |
| Sumatriptan Succinate | 168 | $45,663 |
| Emgality PenGalcanezumab-Gnlm | 46 | $39,670 |
| QuliptaAtogepant | 24 | $25,027 |
| BotoxOnabotulinumtoxina | 22 | $24,052 |
| Aimovig AutoinjectorErenumab-Aooe | 27 | $19,772 |
| Zolmitriptan | 54 | $16,588 |
| Ajovy SyringeFremanezumab-Vfrm | 13 | $10,465 |
| Repatha SureclickEvolocumab | 12 | $6,214 |
| Sumatriptan | 25 | $5,177 |
| Aripiprazole | 28 | $2,636 |
| Naratriptan Hcl | 60 | $2,329 |
| Topiramate | 22 | $1,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $281,114 | $117,36363 claims |
| PfizerNurtec Odt | $5,652 | $59,60234 claims |
| Upsher-smith Laboratories LLCTopiramate | $602 | $1,81722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.